Values as of: 2024-11-13
COMMON STOCK | Medical Devices |
Last Closing
USD 53Change
-2.13 (-3.85)%Market Cap
USD 61.66BVolume
400.00Analyst Target
N/AVerdict
Verdict
Siemens Healthineers AG, through its subsidiaries, develops, manufactures, and sells a range of diagnostic and therapeutic products and services to healthcare providers worldwide. It operates through four segments: Imaging, Diagnostics, Varian, and Advanced Therapies. The Imaging segment provides magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound systems. Its Diagnostics segment offers in-vitro diagnostic products and services to healthcare providers in laboratory and point-of-care diagnostics; and workflow solutions for laboratories and informatics products. The Varian segment provides cancer care technologies, solutions, and services to oncology departments in hospitals and clinics; and technology-enabled optimized workflows, clinical services, and digital solutions and applications for managing treatment and therapy. Its Advanced Therapies segment offers products that are designed to support image-guided minimally invasive treatments in various areas, such as cardiology, interventional radiology, and surgery; and angiography systems and mobile C-arms. It offers essential technical customer service, such as maintenance and repair; medical equipment performance management; training; clinical education and e-learning; planning and design; financing; asset management; and managed departmental services for laboratories and healthcare facilities, as well as digital healthhcare consulting, products, and services. The company is headquartered in Forchheim, Germany. Siemens Healthineers AG operates as a subsidiary of Siemens Aktiengesellschaft.
Company Website : https://www.siemens-healthineers.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| SMMNY | Siemens Healthineers AG ADR |
-0.49 (-1.82%) |
USD 61.36B |
| RYLPF | Koninklijke Philips N.V |
-0.10 (-0.39%) |
USD 23.84B |
| SONVF | Sonova Holding AG |
-0.50 (-0.14%) |
USD 22.14B |
| SNWV | SANUWAVE Health Inc |
+0.44 (+1.96%) |
USD 20.67B |
| SNNUF | Smith & Nephew plc |
N/A |
USD 12.50B |
| WILLF | Demant A/S |
N/A |
USD 8.39B |
| GNGBF | Getinge AB |
N/A |
USD 5.12B |
| AMBBY | Ambu A/S |
N/A |
USD 5.04B |
| AMBFF | Ambu A/S |
N/A |
USD 5.04B |
| GGNDF | GN Store Nord A/S |
-3.21 (-15.10%) |
USD 3.10B |
N/A
| Market Performance vs. Industry/Classification (Medical Devices) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -8.78% | 60% | D- | 45% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | -8.78% | 60% | D- | 45% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | 1.92% | 58% | F | 51% | F | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 1.92% | 58% | F | 52% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | 10.49% | 69% | C- | 66% | D+ | ||
| Dividend Return | N/A | N/A | N/A | N/A | N/A | ||
| Total Return | 10.49% | 69% | C- | 66% | D+ | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 8.32% | 53% | F | 51% | F | ||
| Dividend Return | 8.97% | 53% | F | 48% | F | ||
| Total Return | 0.65% | 48% | F | 17% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 23.43% | 92% | A | 82% | B | ||
| Risk Adjusted Return | 38.29% | 87% | B+ | 75% | C | ||
| Market Capitalization | 61.66B | 100% | F | 98% | N/A | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers median on a price to book value basis.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company has under performed its peers on annual average total returns in the past 5 years.
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
